BDSI announces public offering after paying $30M for drug rights
In a pair of announcements, Raleigh's BioDelivery Sciences International (Nasdaq: BDSI), announced the $30 million acquisition of exclusive U.S. commercialization rights to a Japanese drug. In the hours following that deal, BDSI also announced a public offering of its common stock.
Made by Shionogi, the drug – called Symproic – treats opioid-induced constipation in adult patients with chronic non-cancer pain.
BDSI will pay Shionogi $20 million upfront and another $10 million on the six-month…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news
More News: Cancer & Oncology | Constipation | Health Management | Japan Health | Mergers and Aquisitions | Pain | Pharmaceuticals